FDA Approvals in Oncology: July-September 2024
This quarter’s 16 approvals include a first-in-class cell therapeutic, a flurry of new options for EGFR-mutated lung cancer, and...
Category: FDA Approvals
This quarter’s 16 approvals include a first-in-class cell therapeutic, a flurry of new options for EGFR-mutated lung cancer, and...
New cervical cancer self-screening options and a portable blood test device could lead to changes in at-home cancer screening...
The FDA issued 18 oncology-related approvals in Q2 2024 including two first-in-class drugs and a bispecific T-cell engager for...
The FDA issued 14 oncology approvals this quarter, including the first tumor-infiltrating lymphocyte therapy.
In the final quarter of 2023, the FDA issued 17 approvals specifically for the treatment of tumors.
The AACR Annual Meeting 2023, held April 14-19, commemorated several milestones, including the 25th anniversary of the approval of...
FDA approvals issued in third quarter 2023 included a new treatment for prostate cancer harboring BRCA mutations, two new...